Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Benboubker, L.
Right arrow Articles by Colombat, Ph.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benboubker, L.
Right arrow Articles by Colombat, Ph.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:1485-1491, 2000
© 2000 European Society for Medical Oncology

research-article

A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels

L. Benboubker1,, C. Valat2, C. Linassier1, G. Cartron1, M. Delain1, M. Bout1, F. Fetissof3, T. Lefranq3, J. P. Lamagnere1 and Ph. Colombat1

1Departments of Hematology/oncology, Hôpital Bretonneau Tours, France
2Isotope, Hôpital Bretonneau Tours, France
3Histopathology, Hôpital Bretonneau Tours, France

Correspondence to: L. Benboubker, MD Service d'Oncologie Médicale et Maladies du sang CHR Bretonneau, 2 bvd Tonnellé 37044 Tours Cedex France E-mail: Benboubker{at}bretonneau.chu-tours.fr

BACKGROUND: Serum CA125 (sCA125) was recently reported to be of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma (NHL). This report aims to investigate the prognostic value of a new serologic index combining sCA125 and LDH serum levels.

PATIENTS AND METHODS: One hundred thirty-seven patients were studied, sixty-three with histologically proven low-grade NHL, and seventy-four with a high-grade subtype.

RESULTS: sCA125 and LDH levels were elevated in more than one third of patients. sCA125 was more frequently increased than LDH in low-grade NHL. In this group, complete remission (CR) was achieved in 87, 45, and 0% (P = <2 x 10–6) of patients with normal sCA125 and LDH serum levels (Low-risk group), one parameter increased (Intermediate-risk group), and increased sCA125 and LDH serum levels (high-risk group), respectively. The estimated five-year overall survival was 97%, 67% and 22% for low, intermediate, and high-risk groups, respectively. This combination was the only parameter predictive of RFS and OS in multivariate analysis (P<0.0001).

CONCLUSIONS: In this study the combination of s-LDH and sCA125 levels (normal vs. abnormal) was found to be an important prognostic factor in low-grade lymphoma and may be used in the selection of appropriate therapeutic approaches for individual patients.

CA125, LDH, low-grade, NHL, prognostic factor, serologic index


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
J. Zidan, O. Hussein, W. Basher, and S. Zohar
Serum CA125: A Tumor Marker for Monitoring Response to Treatment and Follow-up in Patients with Non-Hodgkin's Lymphoma
Oncologist, July 1, 2004; 9(4): 417 - 421.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.